Loading
A phase 2 trial of gemcitabine in pancreatic cancer, run by Shenzhen University General Hospital, not yet recruiting.
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients is a phase 2, randomised interventional study registered as NCT06234072 by Shenzhen University General Hospital, with a registry enrolment figure of 120 participants, started 2024-02 and due to reach its primary completion in 2027-01. Interventions recorded: Astragalus + Gemcitabine; Gemcitabine alone. Conditions listed: Pancreatic Cancer. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.